Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP06737947A	2014-06-11	Hollatz, Christian	Patent maintained as amended
EP06737947A	2014-06-11	Hollatz, Christian	Patent maintained as amended
EP06737947A	2014-06-11	PENTAFARMA S.A.	Patent maintained as amended
EP06737947A	2014-06-10	df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB	Patent maintained as amended
EP06760544A	2014-01-24	Taylor Wessing LLP	Revoked
EP06760544A	2014-01-24	Galenicum Health S.L.	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7879828	March, 2015	Terminated-Denied	Wyeth LLC	Apotex Inc.
US7879828	August, 2014	Terminated-Denied	Wyeth LLC	Initiative for Responsibility in Drug Pricing LLC
US7879828	November, 2013	FWD Entered	Wyeth LLC	Apotex Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE40183	PF PRISM CV	7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines	Apr, 2016 (8 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE40086	PF PRISM CV	Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines	Jun, 2013 (10 years ago)
US9254328	PF PRISM CV	Tigecycline compositions and methods of preparation	Mar, 2026 (1 year, 10 months from now)
US9694078	PF PRISM CV	Tigecycline compositions and methods of preparation	Mar, 2026 (1 year, 10 months from now)
US10588975	PF PRISM CV	Tigecycline compositions and methods of preparation	Mar, 2026 (1 year, 10 months from now)
US8975242	PF PRISM CV	Tigecycline compositions and methods of preparation	Oct, 2028 (4 years from now)
US7879828	PF PRISM CV	Tigecycline compositions and methods of preparation	Feb, 2029 (4 years from now)
US8372995	PF PRISM CV	Crystalline solid forms of tigecycline and methods of preparing same	Oct, 2030 (6 years from now)

Tygacil is owned by Pf Prism Cv.

Tygacil contains Tigecycline.

Tygacil has a total of 8 drug patents out of which 2 drug patents have expired.

Expired drug patents of Tygacil are:

Tygacil was authorised for market use on 15 June, 2005.

Tygacil is available in powder;intravenous dosage forms.

Tygacil can be used as method of treating bacterial infections.

The generics of Tygacil are possible to be released after 08 October, 2030.

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-587)	Mar 20, 2012
New Indication(I-588)	Mar 20, 2012
New Indication(I-586)	Mar 20, 2012

Market Authorisation Date: 15 June, 2005

Treatment: Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

Tygacil patents expiration